3,4- dihydroxy- 3,4- dihydro- 7- ethylbenz(a)anthracene (EBAD)

structure given in first source; RN given refers to trans-isomer; RN for cpd without isomeric designation not available 9/88

Also Known As:

EBAD; 7-ethyl-3,4-dihydrobenz(a)anthracene-3,4-diol

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Autonomic Nervous System Diseases (Dysautonomia) 01/01/2018 - "In this vein, Emotional, Behavioural and Autonomic Dysregulation (EBAD) would be a useful construct to target for treatment which could mitigate burden and improve the quality of life of patients.RTT can be considered as a congenital dysautonomia and because EBAD can give rise to impairments occurring in multiple overlapping physiological systems, understanding these physiological responses arising out of EBAD would be a critical part to consider when planning treatment strategies and improving clinical outcomes in these patients. " 01/01/2021 - "Our findings suggest a reasonable association of EDA normalization and symptomatic improvement in RTT subjects with EBAD treated with buspirone and point out its potential application as a measure of dysautonomia in RTT. "
2.	Rett Syndrome (Rett's Disorder) 01/01/2018 - "Key issues in Rett syndrome: emotional, behavioural and autonomic dysregulation (EBAD) - a target for clinical trials." 01/01/2021 - "Emotional Behavioural and Autonomic Dysregulation (EBAD) in Rett Syndrome - EDA and HRV monitoring using wearable sensor technology."
3.	Abscess 07/01/2022 - "The rate of the pelvic abscess was lower in the EBAD group (1/80, 1.3%) than in the DS group (4/83, 4.8%) but with no statistical significance (P = 0.386). "

1.	Buspirone (Buspar)